Shi‐Xun Lu
Impact in
-
- Cancer-related molecular mechanisms research
-
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 11
- Cancer Immunotherapy and Biomarkers 3
- Colorectal Cancer Surgical Treatments 2
- Viral-associated cancers and disorders 2
-
- Gastric Cancer Management and Outcomes 5
- Co-authors
- Jing‐Ping Yun (4 shared papers)Miao‐Zhen Qiu (6 shared papers)Feng‐Hua Wang (5 shared papers)Wen‐Long Guan (5 shared papers)Chris Zhiyi Zhang (2 shared papers)Yuhong Li (3 shared papers)Caiyun He (3 shared papers)Rui‐Hua Xu (3 shared papers)
- Journals
- Nature Communications (1 paper)Journal of Clinical Oncology (1 paper)Cancer Letters (1 paper)Fundamental Research (1 paper)PLoS ONE (1 paper)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Shi‐Xun Lu
21 papers receiving 302 citations
Peers
Comparison fields: 5 of 34
- Cancer Research 58
- Oncology 101
- Hepatology 18
- Pulmonary and Respiratory Medicine 65
- Pathology and Forensic Medicine 25
Countries citing papers authored by Shi‐Xun Lu
This map shows the geographic impact of Shi‐Xun Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shi‐Xun Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shi‐Xun Lu more than expected).
Fields of papers citing papers by Shi‐Xun Lu
This network shows the impact of papers produced by Shi‐Xun Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shi‐Xun Lu. The network helps show where Shi‐Xun Lu may publish in the future.
Co-authors
The 25 scholars most cited alongside Shi‐Xun Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2023 | 66 | |
| 2 | PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. | 2021 | 33 |
| 3 | 2021 | 22 | |
| 4 | 2013 | 22 | |
| 5 | 2019 | 18 | |
| 6 | 2022 | 15 | |
| 7 | 2020 | 15 | |
| 8 | 2018 | 14 | |
| 9 | 2022 | 13 | |
| 10 | 2022 | 13 | |
| 11 | 2021 | 12 | |
| 12 | 2022 | 12 | |
| 13 | 2023 | 11 | |
| 14 | 2024 | 9 | |
| 15 | 2019 | 9 | |
| 16 | 2023 | 7 | |
| 17 | 2023 | 4 | |
| 18 | 2020 | 4 | |
| 19 | 2017 | 3 | |
| 20 | 2017 | 2 |
About Shi‐Xun Lu
Shi‐Xun Lu is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine, Surgery and Hepatology, having authored 22 papers that have together received 306 indexed citations. Recurring topics across this work include Genetic factors in colorectal cancer (5 papers), Gastric Cancer Management and Outcomes (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (2 papers), Cancer Genomics and Diagnostics (2 papers), Colorectal Cancer Surgical Treatments (2 papers) and Viral-associated cancers and disorders (2 papers). The work is most often cited by research in Cancer Research (58 citations), Oncology (101 citations), Hepatology (18 citations), Pulmonary and Respiratory Medicine (65 citations) and Pathology and Forensic Medicine (25 citations). Shi‐Xun Lu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Jing‐Ping Yun, Miao‐Zhen Qiu, Feng‐Hua Wang, Wen‐Long Guan, Chris Zhiyi Zhang, Yuhong Li, Caiyun He, Rui‐Hua Xu, Yuting Sun and Jia-Jian Loh. Their work appears in journals such as Nature Communications, Journal of Clinical Oncology, Cancer Letters, Fundamental Research and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.